ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 57.1% from a year ago
Common stock stood at $11K at the end of Q1 FY2026, up 57.1% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +30.1% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +57.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 11K USD
- Year-over-year change
- +57.1%
- 4-year CAGR
- +28.8%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11K | +57.1% |
| FY2024 | 2024-12-31 | 7K | +16.7% |
| FY2023 | 2023-12-31 | 6K | +20.0% |
| FY2022 | 2022-12-31 | 5K | +25.0% |
| FY2021 | 2021-12-31 | 4K | — |
Common Stock vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's Mar 2026 common stock of $11K is the 5th highest of the 11 companies compared; the peer median is $9K.
- Its year-over-year change of +57.1% is the 2nd highest of 10, against a peer median of +14.3%.
- Common stock amounts to 0.0% of total assets for ORIC, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.43B | +2.4% | +15.3% | 192.0% | |
| Mar 2026 | $636K | +0.8% | +0.9% | 0.3% | |
| Sep 2026 | $74K | +25.4% | +289.3% | 0.0% | |
| Mar 2026 | $60K | +1.7% | +12.6% | 0.0% | |
| Mar 2026 | $11K | +57.1% | +30.1% | 0.0% | |
| Mar 2026 | $9K | +80.0% | -26.3% | 0.0% | |
| Mar 2026 | $9K | +0.0% | +8.7% | 0.0% | |
| Mar 2026 | $8K | +14.3% | +11.9% | 0.0% | |
| Mar 2026 | $6K | +20.0% | +7.7% | 0.0% | |
| Mar 2026 | $5K | +25.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ORIC) | $9K | +14.3% | +10.3% | 0.0% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 226.01M | 66.84M | 23.38M | 59.41M | 45.67M |
| Short-term Investments | 10.97M | 139.43M | 184.8M | 196.55M | 235.82M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.19M | 4.41M | 6.29M | 6.98M |
| Total Current Assets | 240.52M | 210.46M | 212.6M | 262.25M | 288.47M |
| Property, Plant & Equipment (Net) | 2.41M | 14.25M | 12.01M | 2.92M | 9.07M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 43.39M | 22.42M | 27.34M | 0 | 111.25M |
| Tax Assets | 0 | 3.18M | 2.68M | 0 | 2.11M |
| Other Non-current Assets | 12.32M | 49K | 61K | 8.97M | 98K |
| Total Non-current Assets | 58.12M | 39.9M | 42.09M | 11.89M | 122.54M |
| Total Assets | 298.64M | 250.36M | 254.69M | 274.14M | 411M |
| Account Payables | 1.89M | 1.32M | 944K | 1.55M | 3.82M |
| Short-term Debt | 0 | 2.66M | 2.75M | 0 | 3.33M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.8M | 6.09M | 10.23M | 7.65M | 13.26M |
| Total Current Liabilities | 15.15M | 15.39M | 20.46M | 24.85M | 20.42M |
| Long-term Debt | 0 | 0 | 0 | 0 | 4.11M |
| Deferred Tax Liabilities | 0 | 3.18M | 2.68M | 0 | 2.11M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 10.52M | 0 | 0 | 6.17M | (4.11M) |
| Total Non-current Liabilities | 10.52M | 12.62M | 10.14M | 6.17M | 6.22M |
| Total Liabilities | 25.67M | 28.01M | 30.6M | 31.02M | 26.64M |
| Common Stock | 4K | 5K | 6K | 7K | 11K |
| Retained Earnings | (245.11M) | (334.23M) | (434.93M) | (562.77M) | (692.24M) |
| Accumulated OCI | (103K) | (1.29M) | 258K | 379K | 786K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 272.98M | 222.35M | 224.09M | 243.12M | 384.36M |
| Total Debt | 1.93M | 12.1M | 10.21M | 3.18M | 11.55M |
| Net Debt | (224.08M) | (54.74M) | (13.17M) | (56.22M) | (34.12M) |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.